I n January 2005, an FDA Advisory Committee rejected a proposal to allow OTC sales of lovastatin (Mevacor by Merck & Co). 1 Among the criteria considered were the following: a low potential for misuse and abuse, benefits outweigh risks, the drug can be used safely and effectively without health practitioner involvement, patients may use for self-diagnosed conditions, and adequate labeling.
Although the sale of OTC statins could potentially increase access to therapy for a large targeted population, there are several economic and safety issues that have been raised with this potential decision (eg, changes in reimbursement patterns, inadvertent use by pregnant women). 2 One area that may also require additional study is the role of the pharmacist in the screening of appropriate patients and the provision of OTC counseling to promote adherence and safe use of the medication, including follow-up testing. It is important to note that in an open-label, uncontrolled, observational study in a simulated OTC setting, only 19.5% (206/1,509) of the subjects who decided to purchase and use OTC lovastatin met the first three criteria of the package labeling. 3 Labeled criteria included men at least 45 years or women at least 55 years, low-density lipoprotein cholesterol (LDL-C) level between 130 and 170 mg/dL, and one or more of the following CHD risk factors (eg, smoking, hypertension, family history of CHD, high-density lipoprotein cholesterol (HDL-C) level: 1 to 39 mg/dL). 3 The role of the pharmacist in optimizing OTC patient care is one of great importance, particularly in the advent of statin OTC availability. In Britain, where simvastatin has been approved for OTC sales, the interaction between pharmacists and patients has been addressed prior to approval. In the current US proposal considered in January, the patient-pharmacist relationship was not fully explored. Traditionally, the movement of drugs from prescription to OTC status has been directed by the management of conditions that are associated with overt symptoms, typically of short duration. The consideration of drugs for the management of silent diseases (eg, hypertension, diabetes, hyperlipidemia), is a movement that would require considerable patient interaction with pharmacists and physicians. In a study conducted by The National Lipid Association, 85% of pharmacists surveyed were interested in answering questions about an OTC statin, and 79% indicated that they were comfort-able providing advice about OTC statins. 4 Furthermore, 68% of pharmacists identified that there is a need to learn more about the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) treatment guidelines, and 63% were concerned about their ability to obtain sufficient knowledge regarding the patients' health.
As pharmacists, we play a very important role in providing pharmaceutical care. Statins may not be available OTC yet, but when this debate is raised again, the role of the pharmacist should be a vital component in the plan.
